Coya Therapeutics secures global deal with Dr Reddy’s Laboratories

Coya has received an exclusive, royalty-bearing license to sell Dr Reddy’s proposed biosimilar Abatacept in several regions

Coya Therapeutics has secured a global deal with Dr Reddy’s Laboratories to acquire the rights to use Dr Reddy’s proposed Abatacept biosimilar for the production of COYA 302, a combination product designed to treat neurodegenerative disorders.

According to the agreement, Coya has received an exclusive, royalty-bearing license to sell Dr Reddy’s proposed biosimilar Abatacept in several regions, including North and South America, Europe, the UK, and Japan. Coya will compensate Dr Reddy’s for the license by paying a one-time, non-refundable upfront fee.